Bone diseases: Bisphosphonates in osteoporosis - Beyond 5 years

Nature Reviews Rheumatology

Volumn 9, Issue 5, 2013, Pages 263-264

  Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; GERANYLTRANSFERASE; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE MINERAL; BONE REMODELING; BONE TURNOVER; DRUG EFFICACY; DRUG HALF LIFE; FEMUR NECK; FRACTURE; HIP; HUMAN; LONG TERM CARE; LUMBAR SPINE; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; SPINE FRACTURE;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; OSTEOPOROSIS;

EID: 84877598206     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.57     Document Type: Article

References (10)

1. Whitaker, M.,Guo, J., Kehoe, T. & Benson, G. Bisphosphonates for osteoporosis - where do we go from here? N. Engl. J. Med. 366, 2048-2051 (20126p
2. Schwartz, A. V.et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX trial. J. Bone Miner. Res. 25, 976-982 (20106p
3. Black, D. M., Bauer, D. C., Schwartz, A. V., Cummings, S, R & Rosen, C. J. Continuing bisphosphonate treatment for osteoporosis - for whom and for how long? N. Engl. J. Med. 366, 2051-2053 (20126p
4. McNabb, B. L.et al. BMD changes and predictors of increased bone loss in postmenopausal women following a 5year course of alendronate. J. Bone Miner. Res. doi:10.1002/jbmr.1864.6p
5. Black, D. M.et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 296, 2927-2938 (20066p
6. Khan, S. A.et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J. Bone Miner. Res. 12, 1700-1707 (19976p
7. Papapoulos, S. E. & Cremers, S. C. L. M. Prolonged bisphosphonate release after treatment in children. N. Engl. J. Med. 356, 1075-1076 (20076p
8. Landman, J. O.,Hamdy, N. A. T., Pauwels, E. K. J. & Papapoulos, S. E. Skeletal metabolism in patients with osteoporosis after discontinuation of long term treatment with oral pamidronate. J. Clin. Endocrinol. Metab. 80, 3465-3468 (19956p
9. Black, D. M.et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Miner. Res. 27, 243-254 (20126p
10. Eastell, R.,Hannon, R. A., Wenderoth, D., Rodriguez-Moreno, J. & Sawicki, A. Effect of stopping risedronate after long-term treatment on bone turnover. J. Clin. Endocrinol. Metab. 96, 3367-3373 (20116p6p